Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

53 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

AMC-075 Pregnancy Report Form (PRF)

- 29/08/17 - 1 modulo, 5 itemgroups, 22 elementi, 1 linguaggio
Itemgroups: Header - Pregnancy Report Form, Current Pregnancy Information, Previous Pregnancy Information, Relevant Medical History, Comments
AMC-075 Pregnancy Report Form (PRF) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A0F9B852-8D06-8306-E040-BB89AD434EB4

Lymphoma HIV Vorinostat Rituximab NCT01193842 AMC-075 - Pregnancy Outcome Form

- 29/07/17 - 1 modulo, 4 itemgroups, 27 elementi, 1 linguaggio
Itemgroups: Header Module, Pregnancy Status, Pregnancy Outcome Live Birth, Pregnancy Outcome
AMC-075 Pregnancy Outcome Form (PRO) Lymphoma HIV Vorinostat Rituximab NCT01193842 On-Study - AMC-075 Pregnancy Outcome Form (PRO) - 3228008v1.0 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A0F9B852-8D17-8306-E040-BB89AD434EB4

Eligibility Newly Diagnosed Diffuse Large B-Cell Lymphoma NCT01854372

- 22/01/21 - 1 modulo, 2 itemgroups, 28 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.; ODM derived from: https://clinicaltrials.gov/show/NCT01854372

Eligibility B-Cell Lymphoma N1085 NCT01334502

- 20/09/21 - 1 modulo, 5 itemgroups, 74 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria - All responses in section below must be "Yes" unless specified as "NA"., Exclusion Criteria, Registration Check, Registration Check, Grouping Factor
N1085 Eligibility Checklist Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9EAFF494-0322-469D-E040-BB89AD43599E

S1001 Registration Worksheet Step 2

- 28/08/17 - 1 modulo, 7 itemgroups, 14 elementi, 1 linguaggio
Itemgroups: Protocol Information, SWOG PATIENT ID, For SWOG Institutions:, Patient Information, Stratification Questions, Patient Eligibility, Auxiliary Questions
S1001 Registration Worksheet Step 2 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A55DBEC7-1F59-3244-E040-BB89AD43434F

Eligibility Lymphoma, Large B-Cell, Diffuse NCT01156259

- 24/07/20 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT01156259

Eligibility Lymphoma, Large-Cell, Diffuse NCT00135499

- 15/06/16 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00135499

Eligibility Primary Mediastinal B-Cell Lymphoma NCT00944567

- 01/09/18 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00944567

Eligibility Lymphoma, Large Cell, Diffuse NCT00436280

- 04/06/18 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Chemotherapy for Patients With Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00436280

Eligibility Lymphoma, Large B-Cell, Diffuse NCT01157988

- 04/06/18 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01157988

Eligibility Lymphoma, Large B-Cell, Diffuse NCT00655837

- 03/06/18 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL; ODM derived from: https://clinicaltrials.gov/show/NCT00655837

Eligibility Diffuse Large Cell B-lymphoma NCT01325701

- 01/12/19 - 1 modulo, 2 itemgroups, 21 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01325701

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial